Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Dr Brass has published over 85 peer reviewed articles and more than 200 abstracts, primarily in the field of hepatology, in both the areas of clinical and basic science research.

Therapies 115

Therapies Disease Engineering Medical Schools 115

Drug Target Review

MARCH 19, 2024

Our polygenic score will enable the application of these treatments to people that specifically need it through precision medicine by identifying the individual at high genetic risk of low circulating levels of the vitamin. The answer is no because there are both genetic and dietary (environmental) causes for low vitamin A.

Laboratories 106

Laboratories Bioinformatics International Research Laboratories 106

The Pharma Data

NOVEMBER 9, 2020

The trial looked at a combination of Keytruda from Merck and Lenvima from Eisai for the treatment of advanced renal cell carcinoma (RCC). The results from KEYNOTE-581/CLEAR (Study 307) support the potential use of KEYTRUDA plus LENVIMA for the first-line treatment of advanced RCC. Merck , also known as MSD outside of the U.S.

Research Laboratories 52

Research Laboratories Laboratories Treatment Therapies 52

The Pharma Data

DECEMBER 22, 2020

Perlmutter, President, Merck Research Laboratories. “We We hope that the combined efforts of Merck Research Laboratories and A2 Biotherapeutics will enable the application of this ingenious approach to improve the treatment of patients suffering from refractory solid tumors.”. About A2 Biotherapeutics.

Therapies 52

Therapies Research Laboratories Engineering Laboratories 52

The Pharma Data

AUGUST 15, 2021

inhibitor, for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. months (range, 2.8 as assessed by IRC.

Treatment 52

Treatment Disease Clinical Trials Therapies 52

The Pharma Data

SEPTEMBER 11, 2020

. AstraZeneca’s Fasenra (benralizumab) significantly reduced the size of nasal polyps and cut nasal blockage in patients with chronic rhinosinusitis, raising hopes for a new treatment option for this condition. The OSTRO data indicate Fasenra can benefit patients with nasal polyps.”. Source link.

Research Laboratories 52

Research Laboratories Laboratories Treatment Hospitals 52

The Pharma Data

JUNE 2, 2023

Food and Drug Administration (FDA) for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). We look forward to bringing the benefit of this LYNPARZA combination to patients earlier in their treatment.” In the U.S.,

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

The Pharma Data

SEPTEMBER 21, 2020

AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation across the European Union for the first-line maintenance treatment with bevacizumab for patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer. Photo by D Wells. Conor Kavanagh. Source link.

Research Laboratories 52

Research Laboratories Treatment Trials Laboratories 52

The Pharma Data

JULY 12, 2021

It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If View the full release here: [link]. “It

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

SEPTEMBER 28, 2021

Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. This positive CHMP opinion is a crucial breakthrough in bringing a replacement immunotherapy treatment option with KEYTRUDA to appropriate patients in Europe with metastatic triple-negative carcinoma. About Merck.

Research Laboratories 52

Research Laboratories Clinical Research Treatment Disease 52

The Pharma Data

JANUARY 21, 2021

It is not currently authorized for use as a preventative treatment in nursing homes, but Eli Lilly said it intends to work with regulators to try and get the clearances expanded. James Miessler. Source link.

Nurses 52

Nurses Research Laboratories Laboratories Virus 52

The Pharma Data

SEPTEMBER 21, 2020

However, the combo treatment performed better in certain cancers compared to others, reporting a response in 32.3% In another phase II trial, Keytruda plus Lenvima demonstrated an ORR between 9.7-32.3% of highly-treated ovarian cancer patients and 29% of previously treated TNBC patients. Source link.

Research Laboratories 52

Research Laboratories Laboratories Trials Therapies 52

The Pharma Data

JANUARY 26, 2021

In what looks like a breakthrough for COVID-19 treatments, Regeneron’s monoclonal antibody cocktail REGEN-COV (casirivimab and imdevimab) cut infection rates in half and provided full protection against symptomatic COVID-19, according to interim results from a phase 3 trial evaluating the treatment as a passive vaccine.

Vaccine 52

Vaccine Virus Research Laboratories Trials 52

The Pharma Data

APRIL 28, 2023

The ODAC provides the FDA with independent, expert advice and recommendations on marketed and investigational medicines for use in the treatment of cancer. Preventing or delaying radiographic progression is an important clinical endpoint in assessing oncologic treatment and is very relevant to patients, their caregivers and their families.

FDA 40

FDA Trials Research Laboratories Treatment 40

The Pharma Data

APRIL 8, 2021

Since its first approval in renal cell carcinoma nearly two years ago, KEYTRUDA has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Therapies 52

Therapies Disease Research Laboratories Treatment 52

The Pharma Data

JUNE 7, 2023

These results add to the emerging picture of how individualized neoantigen therapy may advance melanoma treatment and the promise it may hold for other types of cancer. Rubin, senior vice president, global clinical development, Merck Research Laboratories.

Clinical Trials 40

Clinical Trials Therapies Research Laboratories Vaccine 40

The Pharma Data

APRIL 28, 2023

Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC), by a vote of 11 to 1 with one abstention, supported FDA approval of LYNPARZA plus abiraterone and prednisone or prednisolone (abi/pred) for the first-line treatment of adult patients with BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC).

FDA 40

FDA FDA Approval Trials Treatment 40

The Pharma Data

SEPTEMBER 7, 2021

First Anti-PD-1 Regimen Approved in China for First-Line Treatment of Advanced Esophageal or GEJ Cancer, Regardless of Histology or PD-L1 Expression. KEYTRUDA Is Now Approved for Eight Indications Across Five Different Types of Cancer in China. KEYTRUDA Is Now Approved for Eight Indications Across Five Different Types of Cancer in China.

Treatment 52

Treatment Research Laboratories Packaging Laboratories 52

Drug Target Review

NOVEMBER 1, 2023

I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

The Pharma Data

SEPTEMBER 1, 2021

Molnupiravir has been shown to be active in several preclinical models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS. Ridgeback markets Ebanga TM for the treatment of Ebola and has a late-stage development pipeline which includes molnupiravir for the treatment of COVID-19.

Laboratories 52

Laboratories Clinical Trials Virus Trials 52

The Pharma Data

MARCH 8, 2021

At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data.”. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment, and prevention of transmission, as well as SARS-CoV-1 and MERS. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

JUNE 25, 2021

We hope to build on this important research and provide new treatment options to kidney cancer patients.”. “As Europe and Japan in combination with axitinib for the first-line treatment of patients with advanced RCC. Median DFS was not achieved in either treatment arm based on event accrual.

Disease 52

Disease Therapies Treatment Medical Schools 52

The Pharma Data

NOVEMBER 22, 2020

The FDA granted Breakthrough Therapy Designation to the drug for RET fusion-positive NSCLC that has progressed after platinum-based chemotherapy, and RET mutation-positive MTC that requires systemic treatment and for which there are no alternative treatments. It holds the rights for the drug in the rest of the world.

FDA 52

FDA Licensing Licensing Treatment 52

The Pharma Data

MARCH 16, 2021

Head of Department CNS Diseases Research at Boehringer Ingelheim. “By By combining our expertise, we hope to make significant steps forward to finding solutions for patients for which there currently is no treatment.”. Hugh Marston, Ph.D., The Lieber Institute for Brain Development.

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

The Pharma Data

MARCH 16, 2021

inhibitor belzutifan (pronounced bell-ZOO-ti-fan), a novel investigational candidate in Merck’s oncology pipeline, for the potential treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), not requiring immediate surgery. in patients with VHL disease-associated RCC. “Von

FDA 52

FDA Disease Trials Research Laboratories 52

The Pharma Data

MARCH 17, 2021

This approval is based on results from the pivotal Phase 3 KEYNOTE-204 trial, in which KEYTRUDA monotherapy demonstrated a significant improvement in progression-free survival (PFS) compared with brentuximab vedotin (BV), a commonly used treatment. KEYTRUDA reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.48-0.88];

Therapies 52

Therapies Treatment Disease Trials 52

KIF1A

MAY 24, 2023

The approach often focuses the patient-voice around a common goal of treatment, be it to inform a clinical endpoint or identify patient demographics for a drug treatment. The story of how we became connected with Dr. Shi is a shining example of the KIF1A Research Network in action. So, let’s plant the seeds early.

Disease 98

Disease Laboratories Research Science 98

The Pharma Data

JUNE 1, 2022

Anderson has led the team of infectious disease biologists that validated and delivered to an emergency use authorization PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), Pfizer’s novel COVID-19 oral treatment. Dr. Anderson joined Pfizer via Wyeth in 2007.

Vaccine 40

Vaccine Research Laboratories Doctors 40

PerkinElmer

MAY 28, 2020

As viruses evolve over time, new, agile research applications need to be created to combat these evasive intruders from exploiting host cells. Unfortunately, the road towards treatment can be time-consuming, especially when utilizing assays with live virus.

Vaccine 52

Vaccine Disease Virus Small Molecule 52

The Pharma Data

JULY 29, 2021

About Kumquat Biosciences Kumquat Biosciences is a privately held drug discovery and development company committed to creating breakthrough medicines for the treatment of cancer. There will be no change to Lilly’s 2021 non-GAAP earnings per share guidance as a result of this transaction.

Small Molecule 52

Small Molecule Immune Response Research Laboratories Laboratories 52

The Connected Lab

APRIL 29, 2020

When time is critical to the success of your laboratory’s mission, you need proven solutions that connect seamlessly and support your end-to-end workflow.

Laboratories 52

Laboratories Vaccine Research Laboratories Treatment 52

The Pharma Data

JULY 21, 2021

mg, 5 mg, and 10 mg) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy. Females of reproductive potential: Exclude pregnancy before the start of treatment. In the EU, VERQUVO (2.5

Treatment 52

Treatment Production Disease Research Laboratories 52

The Pharma Data

NOVEMBER 11, 2021

Joerg Koglin, vice chairman, Global Clinical Development and Therapeutic Area Head, Cardiovascular for Merck Research Laboratories. Ladies of reproductive implicit Exclude gestation before the launch of treatment. Gain a gestation test before the launch of treatment. each time,” saidDr. WARNING EMBRYO-FETAL Toxin.

Clinical Trials 40

Clinical Trials Trials Hospitals Treatment 40

The Pharma Data

JUNE 7, 2022

Li, president, Merck Research Laboratories. Results from the Phase 3 MOVe-OUT study demonstrated the efficacy benefit of LAGEVRIO treatment was generally consistent across patients infected with SARS-CoV-2 variants of concern, Delta, Gamma and Mu. About Merck.

Hospitals 40

Hospitals Research Laboratories Treatment Disease 40

The Pharma Data

OCTOBER 12, 2021

The Award recognizes the research that has the highest translational potential Translational medicine is an interdisciplinary branch in the biomedical field that aims to combine benchside, bedside and community to promote enhancement in prevention, diagnosis, and treatment. This year, Prof.

Research Laboratories 52

Research Laboratories Laboratories Therapies Production 52

The Pharma Data

JUNE 29, 2021

KEYTRUDA is Now Approved in Combination With Platinum- and Fluoropyrimidine-Based Chemotherapy As First-Line Treatment for Certain Patients With Locally Advanced Unresectable or Metastatic Esophageal Carcinoma or HER2-Negative GEJ Adenocarcinoma Whose Tumors Express PD-L1 (CPS ?10).

Therapies 52

Therapies Treatment Disease Clinical Research 52

The Pharma Data

MARCH 13, 2021

Lilly’s chief scientific officer and president of Lilly Research Laboratories. Donanemab has the potential to become a very important treatment for Alzheimer’s disease. As early as nine months (36 weeks) after initiation of treatment, a significant difference in decline by iADRS was observed.

Disease 40

Disease Trials Treatment Medical Schools 40